Gilead Moving Forward On Combo HIV Therapy
This article was originally published in The Pink Sheet Daily
Executive Summary
Gilead expects a deal "shortly" with Bristol-Myers Squibb and Merck to create a fixed-dose combination of Viread, Emtriva and Sustiva